CD45-targeted antibody- radioimmunoconjugate conju 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 
  • ||||||||||  Iomab-B (I-131-apamistamab) / Actinium, Immedica
    131I-Apamistamab Improves Outcomes in Patients 65 Years and Older with Relapsed or Refractory AML (Stars at Night B2 & B3 (Ballroom Level, Henry B. Gonzalez Convention Center); in-person) -  Dec 5, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_720;    
    P3
    Both PIF and TP53 for Iomab B pts were double in frequency compared to the CC patients. Iomab-B was effective in improving outcomes despite advancing age and presence of these very high-risk features.
  • ||||||||||  Iomab-B (I-131-apamistamab) / Actinium
    131I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors (Halls G-H (San Diego Convention Center)) -  Nov 3, 2023 - Abstract #ASH2023ASH_2597;    
    P3
    Pts with R/R AML who have multiple risk factors such as adverse risk cytogenetics, age >65, venetoclax failure, high comorbidity index or poor KPS are typically not considered for alloHCT due to high transplant-related mortality and post-transplant relapse rates. 131I-apamistamab was effective in achieving durable responses in R/R AML pts irrespective of the presence of multiple risk factors and successfully enabled alloHCT in such pts due to its targeted mechanism of action.
  • ||||||||||  cytarabine / Generic mfg.
    Achieving ''Next-Level'' Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision Medicine (Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)) -  Sep 23, 2023 - Abstract #ASH2023ASH_456;    
    The modern management of acute myeloid leukemia (AML) has changed dramatically in recent years as innovative therapeutics, including FLT3, IDH, and BCL2 inhibitors; novel radioimmunoconjugate approaches; and newer epigenetic and targeted therapeutics (eg, menin inhibitors), have overturned the largely cytarabine-based chemotherapy standard of patient care...Each discussion will be supported by mini lectures covering current science and modern clinical decision-making strategies in a diversity of AML settings and patient presentations. Join us to achieve "next-level" care for your patients with AML!
  • ||||||||||  Analysis of CD45 Isoforms Displayed By Human Peripheral Blood Mononuclear Cells () -  Nov 29, 2022 - Abstract #ASH2022ASH_6962;    
    The capability to unveil the ubiquity of CD45RB isoform expression was enabled by concurrent use of exon-specific mAbs. These data indicate a previously unappreciated complexity in human CD45 isoform display, draw caution on simply stratifying CD45 expression on the basis of CD45RA or CD45RO phenotypes, and highlight a broader significance of the CD45RB isoform among human T cells and monocytes, and within the greater human hematologic system.
  • ||||||||||  Iomab-B (I-131-apamistamab) / Actinium, Immedica
    An Ongoing Pilot Study of Targeted Radioimmunotherapy (131-I Apamistamab) Conditioning Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (Hall D (Ernest N. Morial Convention Center)) -  Nov 4, 2022 - Abstract #ASH2022ASH_6475;    
    P1
    Within the last year alone, the FDA approved brexu-cel for adults w/ R/R B-ALL and expanded indications for liso-cel and axi-cel to include DLBCL w/ primary refractory disease or early first relapse...Anti-cytokine therapies beyond tocilizumab (anti-IL-6R mAb) are being investigated for prevention of CRS/ICANS, including lenzilumab (anti-GM-CSF mAb) and anakinra (IL-1R antagonist)...Accordingly, we designed and initiated a pilot study of Iomab-B w/ adoptive cellular therapy (Iomab-ACT; Fig 1A).Study design and Iomab-ACT is a single-institution pilot study of Iomab-B (w/o chemotherapy) as conditioning prior to 19-28z CAR-T in adults w/ R/R B-ALL or DLBCL (NCT04512716)...Unexpected toxicity (given low dose of ARC) observed in 1 pt included severe trilineage cytopenias lasting >8 wks (requiring RBC/PLT transfusion support, G-CSF, romiplostim) w/o marrow hypoplasia and w/o other apparent neoplastic or drug-induced etiology; this met criteria for dose-limiting toxicity and we will monitor in the next 3 pts...Key exploratory objectives include describing changes in circulating immune cells following ARC and 19-28z CAR T-cells w/spectral cytometry using a custom antibody panel (Fig 1B) and cytokine levels in cerebrospinal fluid. We hope to generate preliminary data to guide further study of CD45-targeted ARCs prior to CAR-T and other forms of adoptive cellular therapy.
  • ||||||||||  fludarabine IV / Generic mfg.
    Journal:  Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma. (Pubmed Central) -  Jun 22, 2021   
    Y-DOTA-BC8 was combined with fludarabine and low-dose TBI followed by allogeneic HCT in patients with MM and ≥1 adverse risk characteristic at diagnosis, relapse after autologous transplant, or plasma cell leukemia (PCL)...At a median follow-up of 5 years, the overall survival was 71% (median not reached) and the progression-free survival was 41% (median 40.9 months). The incorporation of CD45-targeted radioimmunotherapy (RIT) into a reduced-intensity allogeneic HCT is well-tolerated and may induce long-term remissions among patients with poor-risk MM, supporting further development of RIT-augmented conditioning regimens for HCT.